Aspirin Interactions and Management

Major Drug Interactions with Aspirin

The American College of Cardiology recommends that combination with oral anticoagulants (warfarin, DOACs) significantly increases bleeding risk (3-6 fold) due to additive antiplatelet effects and potential INR elevation 1
When aspirin is combined with dabigatran or other anticoagulants, there is increased risk of gastrointestinal bleeding through independent mechanisms 2
Triple therapy (aspirin + P2Y12 inhibitor + anticoagulant) causes more bleeding events than dual therapy (P2Y12 inhibitor + anticoagulant) with no additional thrombotic protection 3
All NSAIDs combined with aspirin increase risk of gastrointestinal bleeding through dual mechanisms: direct mucosal injury and impaired healing of small developing ulcers 4
Proton Pump Inhibitors (PPIs) reduce the risk of GI bleeding in patients taking aspirin by 68% 4
PPIs are recommended as gastroprotective agents for patients on aspirin plus other NSAIDs or anticoagulants 4, 3
The American College of Cardiology states that while concerns exist about PPI interactions with clopidogrel, PPIs should not be withheld when clinically indicated 4

For patients with atrial fibrillation, aspirin should not be used for stroke prevention as it is less effective than anticoagulants and increases bleeding risk 5
In patients with stable coronary artery disease and atrial fibrillation, anticoagulation alone is preferred over combination with aspirin 6
After acute coronary syndrome with stent placement in patients requiring anticoagulation, triple therapy should be limited to 1-3 months in high bleeding risk patients 6
Aspirin dose should be limited to 75-100 mg daily when used with anticoagulants 6
A proton pump inhibitor should be added to reduce GI bleeding risk 3

In patients with asthma, aspirin-exacerbated respiratory disease occurs in up to 21% of adults with asthma 1
Aspirin should be stopped 7-10 days before surgery to reduce bleeding risk 1

For patients requiring both aspirin and anticoagulants, limit aspirin use to specific indications (recent stent placement, mechanical heart valves) 3
Use the lowest effective dose of aspirin (75-100 mg daily) 6
Add a PPI for gastroprotection 3
Monitor closely for bleeding complications 2
Discontinue aspirin when no longer indicated (typically after 1-12 months following coronary intervention) 3
Dual antiplatelet therapy (aspirin + clopidogrel) increases moderate bleeding risk (2.1% vs 1.3%) compared to aspirin alone 4
Clopidogrel is the preferred P2Y12 inhibitor when combined with anticoagulants due to lower bleeding risk compared to newer agents like ticagrelor 6

The combination of apixaban with clopidogrel significantly increases bleeding risk and requires careful management, according to the American College of Cardiology, with a recommended limitation of triple therapy to 1-3 months maximum in patients with acute coronary syndrome requiring stent placement who also need anticoagulation for atrial fibrillation 7, 8

The dual antiplatelet/anticoagulant combination of apixaban and clopidogrel substantially increases bleeding risk and should only be used when absolutely necessary with specific time limitations, as stated by the European Heart Journal 8, 7
After the initial high-risk period, transition to dual therapy (apixaban + clopidogrel alone, discontinuing aspirin) is recommended by the European Heart Journal 8

Drug-eluting stents should be avoided in patients requiring long-term triple antithrombotic therapy due to excessive bleeding risk, as advised by the European Heart Journal 8
Never combine apixaban with strong dual CYP3A4 and P-gp inhibitors simultaneously (e.g., ketoconazole, itraconazole, ritonavir) as this dramatically increases apixaban levels, according to Circulation: Arrhythmia and Electrophysiology and European Respiratory Review 7, 9